Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GREENFIELD, Ind.--(BUSINESS WIRE)--With the U.S. Food and Drug Administration (FDA) approval of Zorbium™ (buprenorphine transdermal solution), Elanco Animal Health (NYSE: ELAN) expands its pain management offerings while addressing an unmet need for veterinary practices. A new long-acting medication to control postoperative pain associated with surgical procedures in cats, ZORBIUM provides up to four days of pain control from a single transdermal dose. ZORBIUM is an innovative, transdermal form

Elanco's ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 30 days. ABOUT E

Elanco to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Elanco Animal Health Incorporated (NYSE: ELAN) will consolidate commercial operations for Elanco International and Elanco Europe into one organization under Ramiro Cabral, EVP & President Elanco International. The restructuring includes eliminating approximately 380 positions, including about 20% of Elanco's senior management.

Elanco To Lay Off 20% Senior Management In Organizational Restructure

Elanco Animal Health Inc. ELAN, -0.10% said Tuesday it will cut about 380 jobs globally as part of a restructuring aimed at simplifying the animal health company's organizational structure and to focus investments in priority areas. The job cuts, which represents about 3.7% of the workforce as of the end of 2020, will include reducing senior management by about 20%.

Elanco Animal Health to cut 380 jobs, reduce senior management by 20% as part of restructuring

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced proposed structural changes to simplify the organization as it best positions the company to create long-term value. The changes are intended to reduce organizational complexity, increase productivity, and enable investment in the highest growth and innovation opportunities, helping to offset previously disclosed higher cost pressures and maintaining the company's current path to 60% adjusted gross

Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:50 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELA

Elanco to Participate in the Evercore ISI 4th Annual HealthCONx Conference

GREENFIELD, Ind.--(BUSINESS WIRE)-- #AnimalsAreTheAnswer--Elanco Animal Health Incorporated (NYSE: ELAN) today announces its position as a founding member of the Greener Cattle Initiative, a research consortium that expects to award approximately $5 million over the next five years to support research into tangible, actionable solutions for potentially reducing enteric methane emissions from cattle, a key opportunity to help mitigate climate change. Led by the Foundation for Food & Agriculture Research (FFAR), ea

Elanco Joins Newly-Formed Consortium Advancing Climate-Neutral Cattle Innovation

Elanco Animal Health Incorporated's (ELAN) CEO Jeff Simmons on Q3 2021 Results - Earnings Call Transcript

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2021, provided guidance for the fourth quarter of 2021, and updated guidance for the full year 2021. The results reflect the inclusion of the Bayer Animal Health business Elanco acquired on August 1, 2020. "Our business continues to show good momentum and strong fundamentals since closing the Bayer Animal Health acquisition a year ago, now with our fourth c

Elanco Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance

Elanco Animal Health (NYSE:ELAN) is set to give its latest quarterly earnings report on Friday, 2021-11-05. Here's what investors need to know before the announcement.

Earnings Preview For Elanco Animal Health

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Aveanna Healthcare Holdings

AVAH vs. ELAN: Which Stock Is the Better Value Option?

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announces its inclusion in FORTUNE's 2021 Change the World list, which recognizes companies that have made an important social or environmental impact through their profit-making strategy and operations. This year's publication honored Elanco's shared value initiative “East Africa Growth Accelerator (EAGA)” and ranked Elanco 19th on the list of 53 companies that do well by doing good. With the East Africa Gr

Elanco Animal Health Selected for 2021 FORTUNE's Change the World List

Starboard Value, an activist investor, believes Elanco Animal Health could take a few steps to strengthen its margins.

Activist investor Starboard could spur Elanco to step up its profitability

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2021 financial results on Friday, November 5, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanc

Elanco Confirms Date and Conference Call for Third Quarter 2021 Financial Results Announcement

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced Ellen de Brabander, Ph.D., will become the new executive vice president of Innovation and Regulatory Affairs. de Brabander brings a proven background of accomplishment in animal health research and development, including the development of parasiticide blockbuster NexGard, as well as major vaccine products in Pet Health and Farm Animal. Current executive vice president Aaron Schacht will lead the i

Elanco Announces New Innovation Leader, Additional Strategic Move to Increase Focus on High-Value, Late-Stage Pet Health Pipeline Progress

GREENFIELD, Ind.--(BUSINESS WIRE)--A newly-published white paper, “Pathway to Climate Neutrality for U.S. Beef and Dairy Cattle Production” by Drs. Sara E. Place, chief sustainability officer for Elanco Animal Health (NYSE: ELAN) and Frank M. Mitloehner, professor and director of the CLEAR Center at University of California, Davis, reviews the latest science on the climate change impacts of U.S. cattle production, and arrives at concrete, actionable conclusions. The question of climate change i

Climate-Neutral Beef, Dairy Could Reach Store Shelves by 2050, According to New Research

GREENFIELD, Ind.--(BUSINESS WIRE)-- #animalsaretheanswer--Today, more than 20 global leaders from one of the world's largest industries, animal agriculture, announced their intention to address the interconnected and urgent challenges of climate change and hunger. Signatories represent global meat, milk, fish and egg production — demonstrating their potential impact in addressing climate change and hunger. With just nine years left to curb emissions or see irreversible damage to the planet and a full 30% - 2.3 billio

Animal Agriculture Accepts Challenge to Be Climate Change Solution while Delivering Global Nutrition Needs

GREENFIELD, Ind.--(BUSINESS WIRE)-- #animalsaretheanswer--Global leaders from one of the world's largest industries converged this week at the Sustainable Solutions for Zero Hunger by 2030: A Vision for Animal Agriculture Forum to explore solutions to combat climate change while keeping the world nourished. Held ahead of the United Nation's Food Systems Summit, more than 600 global business leaders, policymakers and key opinion leaders from a dozen countries convened to accelerate existing efforts moving livestock pr

Business Leaders, Global Experts Convene in Effort to Move Livestock Production to Climate-Neutrality and Achieve Zero Hunger

New developments at Elanco Animal Health have raised investor concerns.

This Pet Health Stock Is Down After Earnings -- Here's Why

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Kindred Biosciences. The transaction advances Elanco's access to the fast-growing $1+ billion dermatology market, complementing the company's existing pipeline and increasing R&D capability in biologics and monoclonal antibodies. The acquisition brings three potential dermatology blockbusters expected to launch through 2025, as well as additional R&D program

Elanco Closes Acquisition of Kindred Biosciences

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT ELANCO Elanco Animal Health Incorporated

Elanco to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Elanco's worldwide business, pharmaceuticals, and food additives for pets and farm animals is recession-resistant - and growing rapidly. Since the 2018/2019 spin-off from Eli Lilly, Elanco has struggled to gain its operational and financial footing more than the comparable Zoetis.

Elanco's Tangible Equity Units: Low-Risk Option With A 5% Yield

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Elanco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elanco Animal Health Incorporated - ELAN

Los Angeles, California--(Newsfile Corp. - August 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE: ELAN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Elanco disclosed on August 9, 2021, that it had "received...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Elanco Animal Health Incorporated and Encourages Investors with Losses to Contact the Firm

News for Elanco Animal Health Inc Stock (ELAN)